



Goldman Sachs Pharma Stocks Growth Plan October 2021 Factsheet



This is a marketing factsheet for professionally advised investors. The factsheet is not investment advice from either IDAD or the issuer, and must not be construed as such by advisers or investors. Capital is at risk and subject to Issuer risk.

IDAD Limited is Authorised and Regulated by the Financial Conduct Authority FCA FRN 740499. No part of this publication may be reproduced, copied or distributed without the prior permission in writing of IDAD. All investors should seek advice from a suitably authorised financial adviser and investment must be made via an authorised counterparty.

Goldman Sachs Pharma Stocks Growth Plan October 2021 Factsheet



INVESTMENT DESCRIPTION

A 5 year investment product linked to the performance of 3 Pharmaceutical stocks and the FTSE 100.

Initial Levels are the close of business level of the Underlying Stocks and Index on the product Strike Date.

If on any annual observation date (including the Final Observation date), starting at 12 months after issue date, all Underlying Stocks are at or above the Autocall Trigger, the investment will autocall. In this instance, initial capital plus the payment for each annual period which has elapsed is paid and the investment will end.

If the investment does not autocall, and the Underlying Index is at or above 65% of its initial level on the Final Observation Date, full capital is returned.

If the FTSE 100 is below 65% of its initial level on the Final Observation date, capital return will be reduced on a 1-for-1 basis. For example the Underlying has fallen to 40% of its initial level, 40% of the capital will be returned.

KEY BENEFITS

- Autocall feature potentially shortens the investment term and is triggered by flat markets or declining markets.
- Snowballing payment.
- Early maturity provides an opportunity to re-assess client's wealth strategy.
- Even in flat or negative markets enhanced returns can be delivered.
- Daily pricing in normal market conditions.
- Upside growth linked to Stocks with downside protection linked to the underlying Index

KEY RISKS

- The return is limited to the pre-defined investment terms.
- The growth payment is conditional upon the performance of the Stocks.
- Investors will be exposed to the credit risk of the Issuer. If the Issuer becomes insolvent or cannot make the payments on the product for any other reason, investors could lose some or all of their investment. A decline in the Issuers credit quality is likely to reduce the market value of the product and therefore the price an investor may receive for the product if they were to sell them in the market.
- There is a risk to capital should the Underlying Index breach the Capital Protection Barrier on the Final Observation date.
- Should investors need to sell their investment before maturity, the trading price will likely mean they get back less than they invested.

IDAD was established in 2002 and our approach from the outset, is what we call the "IDAD Difference". The selection of the investments we offer is not decided in terms of profitability alone and when developing investment products, we favour evidence over dogma. We are happy to work with advisers and product providers alike to deliver a range of investment options to suit differing client wealth strategies. We're proud of our approach to business as well as the investments delivered as a result of the "IDAD Difference". We are committed to building upon our reputation for bringing benefits to all involved in the investment process, but most importantly to the clients.

Product Facts & Features

Issuer:	Goldman Sachs & Co
Guarantor:	Goldman Sachs Group Inc
Guarantor Ratings:	Moody's A2, S&P BBB+, Fitch A Source: Goldman Sachs 11.08.2021
Maximum Term:	5 years
Investment Structure:	Reducing Autocall
Autocall Opportunities:	Annually (First observation at 12 months)
Autocall Trigger:	100% of Initial Level (Reducing by 5% in years 3 & 4)
Payment:	GBP = 8.00% Annually
Issue Price:	100%
Capital Risk:	Not capital protected
Capital Protection Barrier:	65% Final level of the FTSE 100 (Observed at maturity only)
Underlying Index:	FTSE 100 Index
Underlying Stocks:	Initial Level AstraZeneca Plc AZN LN Equity GlaxoSmithKline Plc GSK LN Equity Pfizer Inc PFE UN Equity

Key Dates

ISIN:	GBP = XS2359487027
Subscription Period:	11 August 2021 - 28 October 2021
Strike Date:	29 October 2021
Issue Date:	05 November 2021
1st Autocall Observation:	31 October 2022
Final Observation:	29 October 2026
Maturity Payment Date:	05 November 2026
Denominations:	Lots of £1
Minimum Investment:	£1,000

This is a marketing factsheet for professionally advised investors. The factsheet is not investment advice from either IDAD or the issuer, and must not be construed as such by advisers or investors. Capital is at risk.

Goldman, Sachs & Co. Wertpapier GmbH provides financial services. The Company offers investment banking, securities trading, and asset management services. Goldman, Sachs & Co. Wertpapier serves customers worldwide.

Source: Bloomberg 11.08.2021



SUITABILITY

This product may be suitable for investors who:

- Are seeking the opportunity for higher returns than current cash rates at the time this product was launched.
- Are seeking growth rather than income.
- Understand and accept there is a risk to capital and how the Capital Protection Barrier works.
- Understand the impact of global economic issues and how they will affect the product.
- Understand the criteria which will determine the Payments.
- Are looking to invest for the medium term, being happy to remain invested until maturity.
- Can afford to have their cash invested for the full term of the product.
- Wish to use this investment as part of a well-diversified portfolio.
- Understand that the returns are pre-defined and that they will forgo any growth in the Underlying Stocks which exceeds the fixed level available with this investment product.
- Understand the risk to capital in the event of a Issuer default.
- Should they need to sell their investment before maturity, accept that the trading price will likely mean they get back less than they invested.

RATIONALE

Structured products are becoming increasingly popular for investors due to the wide variety of payoffs and levels of protection that can be achieved by the different types of structures that are available.

Autocalls have been one of the most popular structures over the years. With a classic autocall, returns are paid if the Underlying Stocks are at or above the autocall trigger on an observation date.

The Underlying Stocks have been selected in order to support the anticipated delivery of the Payments.

The autocall payoff can bring an early return of capital allowing the opportunity for a re-assessment of investment strategy. The value of this feature cannot be underestimated as it brings with it the opportunity to secure capital value, as well as the chance to take advantage of future market trends.

To manage the capital risk, a final level barrier set at 65% means the FTSE 100 must fall by more than 35% over 5 years before capital is at risk.

Placing Trades

Trade orders should be sent to orders@idad.com

All trades will be settled direct with IDAD's Euroclear a/c 44382


Secondary Market

The Issuing bank will endeavour to provide quotes under normal market conditions for trading purposes upon request, subject to a Bid-Offer spread of 1%. On the secondary market, traded prices will include any accrued interest ("dirty prices").

Sale trades will settle 2 days after the trade date. Trading details as above.

HOW TO INVEST

This product can be traded using Pershing, your chosen custodian that has permissions to trade and settle the product on your behalf. These can range from Pension Providers, Private Banks and Trading Platforms. This should be discussed with your adviser.



Please note that your cash will be in your account with Pershing until the issue date. Settlement then takes place delivery versus payment where the cash will leave your custody account and you will receive your investment holding into your custody account.

FEES AND CHARGES

IDAD will receive a fee from the Issuer for arranging this product. The charge has been fully accounted for in the calculation of the product's structure and is not expected to exceed 1.0%. Therefore this means that an investment of £10,000 will generate income based on £10,000.


There may be separate fees charged by your Financial Adviser and your chosen market Issuer. You should discuss this further with them.



OBSERVATION DATES (Some observations may vary if a bank holiday occurs)

	Observation Date	Early Redemption Date	Autocall Trigger	Early Redemption Value
1	31 October 2022	07 November 2022	100%	108.00%
2	30 October 2023	06 November 2023	100%	116.00%
3	29 October 2024	05 November 2024	95%	124.00%
4	29 October 2025	05 November 2025	90%	132.00%
5	29 October 2026	05 November 2026	90%	140.00%

HOW THE INVESTMENT WORKS



Goldman Sachs Pharma Stocks Growth Plan October 2021 Factsheet



THE UNDERLYINGS

AstraZeneca PLC operates as a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.


GlaxoSmithKline PLC operates as a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

The **FTSE 100** Index is a capitalization-weighted index of the 100 most highly capitalized companies traded on the London Stock Exchange. The equities use an investibility weighting in the index calculation. The index was developed with a base level of 1000 as of December 30, 1983.

Source: Bloomberg 11.08.2021

MOVEMENT IN THE UNDERLYINGS OVER A 15 YEAR PERIOD



15 YEAR BACK-TESTING

Back-testing shows how the investment would have performed historically using data from previous potential strike dates and observations. Although past performance is not an indication of future performance, it can give a factual insight into how the investment would have performed historically.

This 15 year back-test shows the historical data for a full 10 years of 5 year products that could reach the full term.

Of the 2,501 scenarios tested, 100% would have autocalled paying all Payments. 0.00% would reach the full term without autocalling and none of these would have breached the 65% final level barrier.

Autocall Test	Autocalled	%
12 Months	777	31.07%
24 Months	436	17.43%
36 Months	671	26.83%
48 Months	238	9.52%
60 Months	379	15.15%
Total Autocalled	2,501	100%

Total Number Tested	% Autocalled	% Not Autocalled	% That Returned Full Capital	% Barrier Breach	Average Historic Return GBP
2,501	100%	0%	100%	0%	8%

Factsheet Past performance is not a reliable indicator of future performance and should not be used to assess the future returns or risks

Source: Bloomberg 11.08.2021 Data period: 28.07.2006 to 28.07.2021



RISKS

All investments carry risk. Prior to investing in one of our structured products you need to make sure you fully understand the risks you are taking and accept the level of risk offered by the plan.

Having read over the product factsheet and these risks, if there are any areas that you are still unsure about, please consult with your financial adviser who will be able to help you.

Issuer Risk

Your money is being used as a form of loan via the issuing bank in exchange for the returns offered by structured product. The bank is legally committed to honour the terms of the plan. It is possible that the Counterparty may go bankrupt or default on their payment.

Market Risk

Underlying Index performances may be volatile and subject to unpredictable changes over the investment term. The value of your investment is affected by movements in the price of the index and a fall may result in you not receiving any returns, and/or the loss of some or all of your capital. Your investment does not directly invest in the Underlying index therefore you are not eligible for dividends.

Early Redemption Risk

You should be prepared to hold any plan until maturity. It may be possible for you to sell this investment back to the Issuer early; however, they are not obliged to buy it and may stop such purchases at any time without notice. IDAD has no control over this: we act as your settlement agent. If you sell the investment early you may not get back what you initially invested.

Market Disruption Events

It is possible that a market disruption event might occur, such as trading disruption, changes to the index, changes to index providers or changes in tax legislation. In these circumstances, the Issuer has the right to determine whether any adjustments to the terms of a plan are required. These adjustments may include, but are not limited to: adjustments to the opening or final level of the index, postponing observation dates and substitution of an index. The Issuer is required to act in good faith when making these adjustments.

Reinvestment Risk

To invest in a structured product, you need to loan your capital to the Issuer for a set length of time. During this period, a rise or fall in interest rates may present other investment opportunities with a greater yield. You may be able to sell this product back to the Issuer if this situation does occur, however, the price the Issuer offer you may be less than you originally paid.

Inflation Risk

The value of your initial capital and any returns you may receive are not linked to inflation. If inflation is high over the term of the product, your purchasing power may decrease and so the real return could be low or negative.

Taxation Risk

Tax legislation may change during the life of the investment. The tax treatment depends on the individual circumstances of each client and is subject to change. IDAD does not provide tax advice and you should seek independent tax advice if in doubt. It is our current understanding that the returns on this note will be subject to capital gains tax. Further information about tax in the UK is available from the government website: www.gov.uk.

FSCS Protection

This product offers no FSCS protection.

Goldman Sachs Pharma Stocks Growth Plan October 2021 Factsheet



DISCLAIMERS

This factsheet constitutes a financial promotion and has been issued and approved for the purpose of section 21 of the Financial Services and Markets Act 2000 by IDAD Limited which is Authorised and Regulated by the Financial Conduct Authority FCA FRN 740499. All information, including prices, analytical data and opinions contained within this factsheet are believed to be correct, accurate and derived from reliable sources as at the date of the factsheet. The information within this factsheet does not take into account the specific investment objective or financial situation of any person. This material should be read and understood by the investor. If the investor is not a professional client or eligible Counterparty as defined by the FCA or is considered a retail investor, they should seek suitable financial advice before investing, to ascertain the full risks and terms associated with the investment. All investments must be made via an authorised Counterparty. All rights reserved. No part of this publication may be reproduced, copied or distributed without the prior permission in writing of IDAD. Investments may go up or down in value and you may lose some or all of the amount invested. Past performance is not necessarily a guide for the future. Returns from the structured products are at risk in the event of any of the institutions who provide securities for these products default on their financial obligations.

Any financial adviser shall fully disclose to its clients the existence, nature and amount of all fees and commissions it receives in respect of sales of the Note. They must also confirm any such fee or commission complies with all applicable laws and regulations in all relevant jurisdictions and its receipt does not conflict with applicable regulation or any duty to act in the best interest of any person to whom the professional financial adviser owes any such duty.

This sales brochure has not been prepared or reviewed by Goldman Sachs, the issuer of the Underlying securities or any of its affiliates and neither Goldman Sachs nor any of its affiliates or any of its directors, officers or agents accept any responsibility or liability for the contents of this sales brochure.

For further information please contact IDAD at:

2 Rotherbrook Court, Bedford Road, Petersfield, Hampshire GU32 3QG

email: enquiries@idad.com **telephone:** +44(0)1730 779335 **or visit our website** www.idad.com

The Note is/are not in any way sponsored, endorsed, sold or promoted by FTSE International Limited ("FTSE") or the London Stock Exchange Group companies ("LSEG") (together the "Licensor Parties") and none of the Licensor Parties make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to (i) the results to be obtained from the use of the FTSE100 (the "Index") upon which the Note is based, (ii) the figure at which the Index is said to stand at any particular time on any particular day or otherwise, or (iii) the suitability of the Index for the purpose to which it is being put in connection with the Note. None of the Licensor Parties have provided or will provide any financial or Investment advice or recommendation in relation to the Index to Goldman Sachs or to its clients. The Index is calculated by FTSE or its agent. None of the Licensor Parties shall be liable (whether in negligence or otherwise) to any person for any error in the Index or (b) under any obligation to advise any person of any error therein. All rights in the Index vest in FTSE. "FTSE®" is a trade mark of LSEG and is used by FTSE under licence.

IDAD Limited is Authorised and Regulated by the Financial Conduct Authority FCA FRN 740499. No part of this publication may be reproduced, copied or distributed without the prior permission in writing of IDAD. All investors should seek advice from a suitably authorised financial adviser and investment must be made via an authorised counterparty.